Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102


In vivo antitumor effect of an intracellular single-chain antibody fragment against the E7 oncoprotein of human papillomavirus 16.

Accardi L, Paolini F, Mandarino A, Percario Z, Di Bonito P, Di Carlo V, Affabris E, Giorgi C, Amici C, Venuti A.

Int J Cancer. 2014 Jun 1;134(11):2742-7. doi: 10.1002/ijc.28604. Epub 2013 Nov 26.


Retinoblastoma-independent antiproliferative activity of novel intracellular antibodies against the E7 oncoprotein in HPV 16-positive cells.

Accardi L, Donà MG, Mileo AM, Paggi MG, Federico A, Torreri P, Petrucci TC, Accardi R, Pim D, Tommasino M, Banks L, Chirullo B, Giorgi C.

BMC Cancer. 2011 Jan 17;11:17. doi: 10.1186/1471-2407-11-17.


Intracellular expression of a single-chain antibody directed against human papillomavirus type 16 E7 oncoprotein achieves targeted antineoplastic effects.

Wang-Johanning F, Gillespie GY, Grim J, Rancourt C, Alvarez RD, Siegal GP, Curiel DT.

Cancer Res. 1998 May 1;58(9):1893-900.


Naive and radiolabeled antibodies to E6 and E7 HPV-16 oncoproteins show pronounced antitumor activity in experimental cervical cancer.

Phaëton R, Gutierrez J, Jiang Z, Karabakhtsian RG, Albanese J, Sunkara J, Fisher DR, Goldberg GL, Dadachova E.

Immunotherapy. 2015;7(6):631-40. doi: 10.2217/imt.15.18. Epub 2015 Jun 22.


Human Papillomavirus E6/E7-Specific siRNA Potentiates the Effect of Radiotherapy for Cervical Cancer in Vitro and in Vivo.

Jung HS, Rajasekaran N, Song SY, Kim YD, Hong S, Choi HJ, Kim YS, Choi JS, Choi YL, Shin YK.

Int J Mol Sci. 2015 May 29;16(6):12243-60. doi: 10.3390/ijms160612243.


Fusion protein vaccines targeting two tumor antigens generate synergistic anti-tumor effects.

Cheng WF, Chang MC, Sun WZ, Jen YW, Liao CW, Chen YY, Chen CA.

PLoS One. 2013 Sep 13;8(9):e71216. doi: 10.1371/journal.pone.0071216. eCollection 2013.


Prophylactic and therapeutic efficacy of an attenuated Listeria monocytogenes-based vaccine delivering HPV16 E7 in a mouse model.

Jia Y, Yin Y, Duan F, Fu H, Hu M, Gao Y, Pan Z, Jiao X.

Int J Mol Med. 2012 Dec;30(6):1335-42. doi: 10.3892/ijmm.2012.1136. Epub 2012 Sep 20.


SA-4-1BBL as the immunomodulatory component of a HPV-16 E7 protein based vaccine shows robust therapeutic efficacy in a mouse cervical cancer model.

Sharma RK, Srivastava AK, Yolcu ES, MacLeod KJ, Schabowsky RH, Madireddi S, Shirwan H.

Vaccine. 2010 Aug 16;28(36):5794-802. doi: 10.1016/j.vaccine.2010.06.073. Epub 2010 Jul 4.


A novel intracellular antibody against the E6 oncoprotein impairs growth of human papillomavirus 16-positive tumor cells in mouse models.

Amici C, Visintin M, Verachi F, Paolini F, Percario Z, Di Bonito P, Mandarino A, Affabris E, Venuti A, Accardi L.

Oncotarget. 2016 Mar 29;7(13):15539-53. doi: 10.18632/oncotarget.6925.


The contribution of NT-gp96 as an adjuvant for increasing HPV16 E7-specific immunity in C57BL /6 mouse model.

Mohit E, Bolhassani A, Zahedifard F, Taslimi Y, Rafati S.

Scand J Immunol. 2012 Jan;75(1):27-37. doi: 10.1111/j.1365-3083.2011.02620.x.


Vaccination of full-length HPV16 E6 or E7 protein inhibits the growth of HPV16 associated tumors.

Li YL, Qiu XH, Shen C, Liu JN, Zhang J.

Oncol Rep. 2010 Nov;24(5):1323-9.


DNA vaccine encoding HPV-16 E7 with mutation in L-Y-C-Y-E pRb-binding motif induces potent anti-tumor responses in mice.

Bahrami AA, Ghaemi A, Tabarraei A, Sajadian A, Gorji A, Soleimanjahi H.

J Virol Methods. 2014 Sep;206:12-8. doi: 10.1016/j.jviromet.2014.05.013. Epub 2014 May 29.


A Chlamydomonas-derived Human Papillomavirus 16 E7 vaccine induces specific tumor protection.

Demurtas OC, Massa S, Ferrante P, Venuti A, Franconi R, Giuliano G.

PLoS One. 2013 Apr 23;8(4):e61473. doi: 10.1371/journal.pone.0061473. Print 2013.


Control of cervicovaginal HPV-16 E7-expressing tumors by the combination of therapeutic HPV vaccination and vascular disrupting agents.

Zeng Q, Peng S, Monie A, Yang M, Pang X, Hung CF, Wu TC.

Hum Gene Ther. 2011 Jul;22(7):809-19. doi: 10.1089/hum.2010.071. Epub 2011 Mar 9.


An enhanced heterologous virus-like particle for human papillomavirus type 16 tumour immunotherapy.

Jemon K, Young V, Wilson M, McKee S, Ward V, Baird M, Young S, Hibma M.

PLoS One. 2013 Jun 14;8(6):e66866. doi: 10.1371/journal.pone.0066866. Print 2013.


Combined E7-dendritic cell-based immunotherapy and human sodium/iodide symporter radioiodine gene therapy with monitoring of antitumor effects by bioluminescent imaging in a mouse model of uterine cervical cancer.

Jeon YH, Lee HW, Lee YL, Kim JE, Hwang MH, Jeong SY, Lee SW, Ahn BC, Ha JH, Lee J.

Cancer Biother Radiopharm. 2011 Dec;26(6):671-9. doi: 10.1089/cbr.2011.1081. Epub 2011 Nov 17.


Subcellular localization of the human papillomavirus 16 E7 oncoprotein in CaSki cells and its detection in cervical adenocarcinoma and adenocarcinoma in situ.

Dreier K, Scheiden R, Lener B, Ehehalt D, Pircher H, Müller-Holzner E, Rostek U, Kaiser A, Fiedler M, Ressler S, Lechner S, Widschwendter A, Even J, Capesius C, Jansen-Dürr P, Zwerschke W.

Virology. 2011 Jan 5;409(1):54-68. doi: 10.1016/j.virol.2010.09.024. Epub 2010 Oct 23.


Honeybee venom possesses anticancer and antiviral effects by differential inhibition of HPV E6 and E7 expression on cervical cancer cell line.

Kim YW, Chaturvedi PK, Chun SN, Lee YG, Ahn WS.

Oncol Rep. 2015 Apr;33(4):1675-82. doi: 10.3892/or.2015.3760. Epub 2015 Jan 28.


Supplemental Content

Support Center